<DOC>
	<DOCNO>NCT00543608</DOCNO>
	<brief_summary>The purpose study compare clinical cure rate two dose regimen iclaprim vancomycin ( every 12 hour [ q12h ] ) treatment patient hospital-acquired pneumonia ( HAP ) , ventilator-associated pneumonia ( VAP ) , health-care-associated pneumonia ( HCAP ) suspect confirmed due Gram-positive pathogen .</brief_summary>
	<brief_title>Clinical Efficacy Intravenous Iclaprim Versus Vancomycin Treatment Hospital-Acquired , Ventilator-Associated , Health-Care-Associated Pneumonia</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Ventilator-Associated</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<mesh_term>Iclaprim</mesh_term>
	<criteria>Suspected confirm acute bacterial pneumonia due Grampositive pathogens one follow subgroup : hospitalacquired pneumonia ( HAP ) , i.e. , pneumonia occur 48 hour admission , incubate time admission ; ventilatorassociated pneumonia ( VAP ) , i.e. , pneumonia arise 48 hour endotracheal intubation ; healthcareassociated pneumonia ( HCAP ) , i.e. , pneumonia diagnose within 48 hour hospital admission , patient fulfills least one follow criterion : 1. hospitalization least two day within 90 day current infection , 2. residence nursing home longterm care facility , 3. recipient intravenous antibiotic therapy , chemotherapy , wound care within 30 day current infection Acute Physiology Chronic Health Enquiry ( APACHE ) II score &lt; 8 â‰¥ 25 . Pneumonia require empiric target treatment effective Grampositive pathogen . Pulmonary infection due Grampositive organism know resistant either study medication prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>pneumonia</keyword>
	<keyword>nosocomial pneumonia</keyword>
</DOC>